Published Paper Details:

Pharmacogenomics, which examines the influence of genetic variations on drug reactions, has transformed personalized medicine. By customizing treatment to a person's distinct genetic profile, and pharmacogenetic data to fingerprint the pharmacological treatment of neuropsychiatric late-life conditions throughout the analysis of metabolizing enzymes and transporters of psychotropic drugs, mainly those of the cytochrome P450 (CYP) family. Pharmacodynamic response measures as treatment effects mediated through targets (i.e., receptors in the brain) may also contribute to this image. Drug treatment outcome represents a complex phenotype, encoded by dozens, if not hundreds, of genes, and affected by many environmental factors; therefore, we will almost always see a gradient of response. Phenotyping assays of blood enzyme activities (if feasible) are generally more successful than DNA genotyping for predicting unequivocal outcomes of drug therapy in each and every patient. Genotyping to predict drug disposition, efficacy, toxicity, and clinical outcome has been proposed, but the success of genotyping in individualized drug therapy currently appears unlikely because of the many shortcomings (frequency of DNA variant sites, ethnic difference differences, admixture), Genomics is an important tool in basic research; yet, it is unrealistic to include genotyping within the realm of tests available to the practicing clinician in the foreseeable future. Personalized medicine involves the selection of the safest and most effective pharmacological treatment based on the molecular characteristics of the patient. In the case of anticancer drugs, tumour cell alterations can have a great impact on drug activity and, in fact, most Pharmacogenomics studies how genetic affect drug responses and has revolutionized personalized medicine. Pharmacogenomics into clinical practice allows healthcare professionals to make better informed treatment choices, resulting in enhanced patient outcomes. according to a person's specific genetic makeup, pharmacogenomic targeted therapy seeks to enhance treatment effectiveness and reduce negative side effects. This review offers an extensive summary of the pharmacological results related to pharmacogenomic targeted therapy, emphasizing its advantages, obstacles, and future prospects.